Scienture Holdings shares surge 11.51% intraday after Q3 revenue jump from Arbli sales and debt reduction.

Scienture Holdings (SCNX) surged 11.51% intraday following the release of its Q3 2025 financial results, which highlighted a revenue jump driven by increased Arbli sales, and the announcement of formulary additions covering 100 million lives. The stock also benefited from news of full repayment and conversion of outstanding debentures, strengthening its balance sheet, as well as expanded market access through agreements with 2,500 healthcare institutions. These developments, including commercial sales initiation and PBM-led rebate deals, reinforced investor confidence in the company’s hypertension drug commercialization progress and financial stability.